Accession PRJCA005389
Title Selective androgen receptor degrader (SARD) to overcome antiandrogen resistance in castration-resistant prostate cancer
Relevance Medical
Data types Transcriptome or Gene expression
Organisms Homo sapiens
Description Clinical resistance such as androgen receptor (AR) mutation, AR overexpression and AR splice variants restrict the second-generation antiandrogens benefit in castration-resistant prostate cancer (CRPC) patients. Several strategies have been involved in the development of novel antiandrogens to circumvent the occurring resistance. In this work, based on rational drug design, we discovered and identified a bifunctional small molecule Z15 as a potent AR antagonist and the AR selective degrader. Here, in this bioproject, we performed a RNA-seq to analysis the influence of Z15 on prostate cancer cells.
Sample scope Monoisolate
Release date 2021-06-07
Publication
PubMed ID Article title Journal name DOI Year
36656639 Selective androgen receptor degrader (SARD) to overcome antiandrogen resistance in castration-resistant prostate cancer eLife 10.7554/eLife.70700 2023
Grants
Agency program Grant ID Grant title
National Natural Science Foundation of China (NSFC) General Program 22077115
National Natural Science Foundation of China (NSFC) General Program 81672559
National Natural Science Foundation of China (NSFC) General Program 81311120299
Submitter Jinmign    Zhou  (zhou_jim@hotmail.com)
Organization Zhejiang normal university
Submission date 2021-06-07

Project Data

Resource name Description
BioSample (12)  show -